GBT’s Intelligent, Human Vitals qTerm Device Patent; Granted.

Rhea-AI Summary

GBT Technologies Inc. has been granted a non-provisional patent for its machine learning-driven health device, qTerm. The device measures human body temperature, blood oxygen, and heart rate, with plans for future releases to include blood pressure measurement and enhanced AI-driven analytics. The patent also covers the device's ability to function as a telemedicine technology through web and mobile applications. GBT plans to file a continuation patent for qTerm to strengthen its intellectual property.

Positive

• GBT Technologies Inc. has been granted a non-provisional patent for its machine learning-driven health device, qTerm. The patent strengthens the company's intellectual property and provides a competitive advantage in the market.
• The device measures human body temperature, blood oxygen, and heart rate, making it a valuable tool for monitoring vital signs.
• The device's ability to function as a telemedicine technology through web and mobile applications expands its potential user base and market reach.
• Future releases of the device will include blood pressure measurement and enhanced AI-driven analytics, offering additional features and benefits for users.

Negative

• None.

The patent was granted on May 2, 2023, and protects machine learning-driven, health device.

SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”) machine learning-Driven, human vitals device, non-provisional patent application was granted on May 2, 2023, U.S. patent number 11,638,523.

qTerm non-provisional patent was filed on August 3, 2020, describing an intelligent, electronic health device to measure human vitals with a touch of a finger, which has been assigned an internal project name qTerm. The Company successfully completed the development of a fully working prototype in 2022 including robust testing, debugging and a participant’s study.

qTerm measures human body temperature, blood oxygen and heart rate vitals. Future releases are planned to include blood pressure measurement and enhanced, AI-driven analytics. The device is accompanied by a smartphone mobile app and synchronized web application to keep measurements history and provide analytics for user's records at a later phase.

The device can function as a telemedicine technology through web and mobile applications, enabling direct access to user’s data anywhere around the world. The patent describes advanced AI technology to monitor the user’s vitals, performing analytics and provide health related notifications and alerts. GBT plans to file a continuation patent for qTerm, further strengthening the IP concepts. For more information visit qTerm™ | Vital Signs Al Device.

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact:
Dr. Danny Rittman, CTO
press@gopherprotocol.com

FAQ

What is qTerm?

qTerm is a machine learning-driven health device developed by GBT Technologies Inc. It measures human body temperature, blood oxygen, and heart rate, with plans for future releases to include blood pressure measurement and enhanced AI-driven analytics.

What does the granted patent cover?

The granted patent covers the intellectual property of qTerm, providing GBT Technologies Inc. with a competitive advantage in the market.

What are the potential uses of qTerm?

qTerm can be used to monitor vital signs and can also function as a telemedicine technology through web and mobile applications, allowing users to access their data from anywhere in the world.

What are the future plans for qTerm?

GBT Technologies Inc. plans to file a continuation patent for qTerm to further strengthen its intellectual property. Future releases of the device will include blood pressure measurement and enhanced AI-driven analytics.